Watch CBS News

Pfizer COVID-19 vaccine found safe and 100% effective in 12- to 15-year-olds, company says

Pfizer says COVID vaccine effective for kids
Pfizer study finds COVID-19 vaccine is 100% effective, safe for kids 12 to 15 06:48

Pfizer announced Wednesday that its COVID-19 vaccine is safe and strongly protective in kids as young as 12, a step toward possibly beginning shots in that age group before they head back to school in the fall.

Most COVID-19 vaccines being rolled out worldwide are for adults, who are at higher risk from the coronavirus. Pfizer's vaccine is authorized for ages 16 and older. But vaccinating children of all ages will be critical to stopping the pandemic - and helping schools, at least the upper grades, start to look a little more normal after months of disruption.

In a study of 2,260 U.S. volunteers aged 12 to 15, preliminary data showed there were no cases of COVID-19 among fully vaccinated adolescents compared to 18 among those given placebo shots, Pfizer reported.

Pfixer said the study "demonstrated 100% efficacy and robust antibody responses, exceeding those recorded earlier in vaccinated participants aged 16 to 25 years old, and was well tolerated."

It's a small study and hasn't yet been published, so another important piece of evidence is how well the shots revved up the kids' immune systems. Researchers reported high levels of virus-fighting antibodies, somewhat higher than were seen in studies of young adults.

COVID cases soar among youth as U.S. braces for fourth wave 02:52

Kids had side effects similar to young adults, the company said. The main ones are pain, fever, chills and fatigue, particularly after the second dose. The study will continue to track participants for two years for more information about long-term protection and safety.

Pfizer and its German partner BioNTech in the coming weeks plan to ask the U.S. Food and Drug Administration and European regulators to allow emergency use of the shots starting at age 12.

"We share the urgency to expand the use of our vaccine," Pfizer CEO Albert Bourla said in a statement. He expressed "the hope of starting to vaccinate this age group before the start of the next school year" in the United States.

BioNTech CEO and co-founder Ugur Sahin said in a statement that, "Across the globe, we are longing for a normal life. This is especially true for our children. The initial results we have seen in the adolescent studies suggest that children are particularly well protected by vaccination, which is very encouraging given the trends we have seen in recent weeks regarding the spread of the B.1.1.7 UK variant" first identified in Britain.

Pfizer isn't the only company seeking to lower the age limit for its vaccine. Results also are expected soon from a U.S. study of Moderna's vaccine in 12- to 17-year-olds.

But in a sign that the findings were promising, the FDA already allowed both companies to begin U.S. studies  in children 11 and younger, working their way to as young as 6-month-old.

AstraZeneca last month began a study of its vaccine among 6- to 17-year-olds in Britain. Johnson & Johnson is planning its own pediatric studies. And in China, Sinovac recently announced it has submitted preliminary data to Chinese regulators showing its vaccine is safe in children as young as 3.

While most COVID-19 vaccines being used globally were first tested in tens of thousands of adults, pediatric studies won't need to be nearly as large. Scientists have safety information from those studies and from subsequent vaccinations in millions more adults.

One key question is the dosage: Pfizer gave the 12-and-older participants the same dose adults receive, while testing different doses in younger children.

It's not clear how quickly the FDA would act on Pfizer's request to allow vaccination starting at age 12. Another question is when the country would have enough supply of shots - and people to get them into adolescents' arms - to let kids start getting in line.

Supplies are set to steadily increase over the spring and summer, at the same time states are opening vaccinations to younger, healthier adults who until now haven't had a turn.

Children represent about 13% of COVID-19 cases documented in the U.S. And while children are far less likely than adults to get seriously ill, at least 268 have died from COVID-19 in the U.S. and more than 13,500 have been hospitalized, according to a tally by the American Academy of Pediatrics. That's more than die from the flu in an average year. In addition, a small number have developed a serious inflammatory condition linked to the coronavirus.

View CBS News In
CBS News App Open
Chrome Safari Continue
Be the first to know
Get browser notifications for breaking news, live events, and exclusive reporting.